Fate Therapeutics, Inc. (NASDAQ:FATE - Free Report) - Investment analysts at HC Wainwright issued their Q2 2025 earnings per share (EPS) estimates for shares of Fate Therapeutics in a note issued to investors on Wednesday, July 2nd. HC Wainwright analyst R. Burns expects that the biopharmaceutical company will post earnings of ($0.44) per share for the quarter. The consensus estimate for Fate Therapeutics' current full-year earnings is ($1.63) per share. HC Wainwright also issued estimates for Fate Therapeutics' Q3 2025 earnings at ($0.45) EPS and Q4 2025 earnings at ($0.46) EPS.
Fate Therapeutics (NASDAQ:FATE - Get Free Report) last released its quarterly earnings data on Tuesday, May 13th. The biopharmaceutical company reported ($0.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.39) by $0.07. The business had revenue of $1.63 million during the quarter, compared to analysts' expectations of $1.18 million. Fate Therapeutics had a negative return on equity of 47.17% and a negative net margin of 1,318.93%.
Other research analysts have also recently issued reports about the company. Needham & Company LLC reaffirmed a "hold" rating on shares of Fate Therapeutics in a research report on Thursday, June 12th. Stifel Nicolaus reduced their target price on Fate Therapeutics from $5.00 to $3.00 and set a "hold" rating for the company in a report on Thursday, March 6th. Wells Fargo & Company reduced their target price on Fate Therapeutics from $5.00 to $4.00 and set an "equal weight" rating for the company in a report on Thursday, March 6th. Barclays reduced their target price on Fate Therapeutics from $10.00 to $2.00 and set an "overweight" rating for the company in a report on Wednesday, May 14th. Finally, Wedbush reissued a "neutral" rating and issued a $5.00 target price on shares of Fate Therapeutics in a report on Thursday, March 6th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and one has issued a buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and an average price target of $3.83.
Read Our Latest Stock Analysis on Fate Therapeutics
Fate Therapeutics Stock Performance
NASDAQ:FATE opened at $1.15 on Friday. The stock has a 50-day simple moving average of $1.21 and a 200-day simple moving average of $1.23. The stock has a market cap of $131.22 million, a P/E ratio of -0.77 and a beta of 2.18. Fate Therapeutics has a 1 year low of $0.66 and a 1 year high of $5.92.
Institutional Trading of Fate Therapeutics
Hedge funds have recently added to or reduced their stakes in the stock. CWM LLC lifted its holdings in shares of Fate Therapeutics by 899.6% in the 1st quarter. CWM LLC now owns 41,435 shares of the biopharmaceutical company's stock valued at $33,000 after buying an additional 37,290 shares during the period. Graham Capital Management L.P. acquired a new stake in shares of Fate Therapeutics in the 4th quarter valued at approximately $37,000. Brevan Howard Capital Management LP acquired a new stake in shares of Fate Therapeutics in the 4th quarter valued at approximately $41,000. Caption Management LLC acquired a new stake in shares of Fate Therapeutics in the 1st quarter valued at approximately $45,000. Finally, Jane Street Group LLC lifted its holdings in shares of Fate Therapeutics by 106.9% in the 1st quarter. Jane Street Group LLC now owns 63,691 shares of the biopharmaceutical company's stock valued at $50,000 after buying an additional 32,911 shares during the period. 97.54% of the stock is owned by institutional investors and hedge funds.
Fate Therapeutics Company Profile
(
Get Free Report)
Fate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Fate Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fate Therapeutics wasn't on the list.
While Fate Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
